Showing a trial related to 

Closing Soon

Drug for Rosacea, sponsored by Cutanea Life Sciences, Inc.

Get in touch This trial recruits from October 2015 for 104 weeks

TKL Research, Inc.

Phone: 201-587-0500

Inclusion Criteria

Age: From 18 Years To N/A

Gender: Both

Inclusion Criteria

  1. Healthy, male and nonpregnant female subjects, 18 years of age or older.

  2. A diagnosis of severe papulopustular rosacea using the Investigator Global Assessment grading scale at baseline

  3. Subjects with the presence of telangiectasia at Baseline

  4. Subjects with the presence of facial erythema associated with their rosacea at Baseline

Exclusion Criteria

  1. Subjects with steroid rosacea or subtype 3 (phymatous rosacea).

  2. Subjects with nodular rosacea

  3. Standard exclusion criteria.

Exclusion Criteria

NCT02576847

A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects With Rosacea

Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel

View record on ClinicalTrials.gov